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Abstract
The target of rapamycin (TOR) plays a central role in eukaryotic cell growth control1. With 
prevalent hyper-activation of the mTOR pathway in human cancers2, novel strategies to enhance 
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TOR pathway inhibition are highly desirable. We used a yeast-based platform to identify small-
molecule enhancers of rapamycin (SMERs) and discovered an inhibitor of the SCFMet30 ubiquitin 
ligase (SMER3). The large SCF (Skp1-Cullin-F-box) family of ubiquitin ligases performs 
important functions in diverse cellular processes including transcription, cell-cycle control, and 
immune response3. Accordingly, there would be great value in developing SCF ligase inhibitors 
that act by a defined mechanism to specifically inactivate ligase activity. We show here that 
SMER3 selectively inhibits SCFMet30 in vivo and in vitro, but not the closely related SCFCdc4. Our 
results demonstrate that there is no fundamental barrier to obtaining specific inhibitors to modulate 
function of individual SCF complexes, and suggest new strategies for combination therapy with 
rapamycin.
Conserved from yeast to humans, the target of rapamycin (TOR) protein is a serine/
threonine protein kinase that controls various aspects of cellular growth by regulating 
translation, transcription, autophagy, cytoskeletal organization, and metabolism1. 
Rapamycin, a secondary metabolite produced by Streptomyces hygroscopicus, specifically 
inhibits the activity of TOR resulting in starvation-like phenotypes. Over the past few years, 
deregulation of pathways upstream and downstream of mammalian TOR (mTOR) has been 
implicated in a variety of cancers, making the TOR signaling pathway a potential target for 
cancer therapy and rapamycin (and its analogs) an attractive anti-cancer agent2. Results from 
first round clinical trials suggest that different types of tumors have different sensitivities to 
rapamycin and in many cases rapamycin does not completely halt the progress of disease4, 5, 
thus making it desirable to identify small molecules that can act in concert with rapamycin. 
Although combination strategies taking advantage of known interacting pathways (e.g., 
mTOR and IGF1R, PI3K or AKT) are being enthusiastically pursued6-8, an unbiased search 
for novel exploitable pathways has not been reported. The unbiased cell-based approach as 
described here has the potential to elucidate new interactions of TOR signaling with other 
pathways and to provide valuable chemical tools to study signaling networks in various 
settings.
We and others have previously shown that yeast is a promising platform for high-throughput 
discovery of small molecule modifiers of rapamycin-sensitive TOR functions, including 
both suppressors (SMIRs) and enhancers (SMERs), which show translatable potential for 
modulating TOR-related processes in higher organisms9, 10. Here we used the yeast-based 
screen to identify new SMERs targeting cell growth control (Supplementary Information). 
Using a ChemBridge DiverSet library containing 30,000 small molecules, we identified 
>400 compounds that, in the presence of a sub-optimal rapamycin concentration, gave a “no 
growth” phenotype (Supplementary Dataset 1). After gating out toxic compounds using 
unrelated screening datasets (Supplementary Information), a total of 86 potential SMERs 
were identified, which were synthetic sick/lethal with rapamycin but showed little toxicity 
by themselves at the concentrations used (Supplementary Dataset 2 and Supplementary Fig. 
1). The SMERs encompass a variety of modes of action and biological activities, including 
direct inhibition of mTOR kinase activity, new post-translational regulation of mTOR 
function, and inhibition of patient-derived brain tumor initiating cells (manuscripts in 
preparation). Five structurally distinct molecules that exhibited differing effects on growth 
(Supplementary Information) were selected for further analysis (Fig. 1a).
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The primary challenge for phenotype-based chemical genetic screens is the subsequent 
target identification, for which a variety of technologies—from affinity to genomics based—
have been developed (see ref 11 and reviews therein). For our first efforts toward 
understanding SMER targets, we sought to take advantage of the tremendous information on 
gene expression related to various cellular pathways in yeast and performed genome-wide 
expression profiling using DNA microarrays. We hoped to link expression profile changes 
induced by SMERs with gene expression changes caused by genetic perturbations. This 
seemed an effective and elegant approach for target identification12 and only requires that 
the potential drug target(s) be present in the cell. In order to capture early/direct 
transcriptome changes and avoid secondary effects, cells were treated with SMERs for a 
short period (30 min) and the extracted RNA was processed to probe Affymetrix GeneChips 
(Supplementary Information). Two classical ways of analyzing gene expression data are 
hierarchical clustering and principal components analysis (PCA). As shown in Fig. 1b, the 
clustering pattern of our microarray data classified the five SMERs identified from the 
screen into three distinct groups. Treatment of yeast cells with SMER2, 4 or 5 had no 
obvious effect on global gene transcription, whereas SMER1's effect on transcription shared 
extensive similarity with rapamycin (M.A. et al., in preparation). SMER3's expression 
profile, on the other hand, is different from all the others. Consistent with hierarchical 
clustering, principal components analysis (Fig. 1c) also readily distinguishes these effects on 
gene expression.
We focused primarily on SMER3 given its distinct profile. Interestingly, a set of methionine 
biosynthesis genes (referred to as MET-genes hereafter) was upregulated in SMER3-treated 
cells (Supplementary Tables 1-2). GO analysis revealed that, in addition to the enrichment 
of sulfur metabolism genes among the induced group, genes involved in cell-cycle 
regulation were overrepresented in the downregulated group of SMER3-specific genes 
(Supplementary Tables 1-2).
Induction of MET-gene expression in response to SMER3 exposure suggested that the 
cellular pathway controlling homeostasis of sulfur-containing compounds was a possible 
target for SMER3. The key regulator of this pathway is the ubiquitin ligase SCFMet30, which 
restrains the transcriptional activator Met4 in an inactive state in methionine-replete medium 
by attachment of a regulatory ubiquitin chain13. Inactivation of SCFMet30 prevents Met4 
ubiquitination, permitting the formation of an active Met4-containing transcription complex 
that induces expression of the MET-genes and blocks cell proliferation. One hypothesis to 
explain the MET-gene activation and growth inhibition in SMER3-treated cells is that 
SMER3 inhibits SCFMet30. In agreement with this notion, Met4 ubiquitination was blocked 
in cells exposed to SMER3 (but not rapamycin) (Fig. 2a). Furthermore, genetic analyses 
have previously demonstrated that deubiquitinated Met4 mediates cell cycle arrest upon 
inactivation of SCFMet30 (ref 13), and deletion of MET4 rescues lethality of met30Δ (ref 14). 
Notably, met4Δ cells were also less susceptible to growth inhibition by SMER3 (but not 
rapamycin, exemplifying specificity) (Fig. 2b and Supplementary Fig. 2). These findings are 
consistent with SMER3 being an inhibitor of SCFMet30. However, the incomplete resistance 
of met4Δ to SMER3 (Fig. 2b) suggests that SMER3 likely has additional targets other than 
SCFMet30 and that cell growth inhibition by SMER3 is not solely due to SCFMet30 
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inhibition. This is not uncommon as even Gleevec, which was originally believed to be a 
highly specific inhibitor of BCR-Abl, is now appreciated to exert its biological effects 
through protein kinases in addition to its intended target15.
SMER3 enhances rapamycin's effect and also inhibits SCFMet30, suggesting a connection 
between the TOR and SCFMet30 pathways. To test whether SMER3 functions as an enhancer 
of rapamycin through inhibition of SCFMet30 we asked if genetic inhibition of SCFMet30 
could mimic SMER3 in the synergistic effect with rapamycin. Indeed, hypomorphic alleles 
of the individual components of SCFMet30 and its E2 ubiquitin conjugating enzyme, Cdc34, 
were hypersensitive to rapamycin (Fig. 2c). The synthetic lethality with rapamycin appears 
to arise largely from reduced SCFMet30 activity because inhibition of Cdc4, which forms a 
related, essential SCFCdc4 ubiquitin ligase, only resulted in minor rapamycin 
hypersensitivity (Fig. 2c). Together these results suggest that SMER3 enhances rapamycin's 
growth inhibitory effect by inhibition of SCFMet30.
To test whether SMER3 can directly inhibit SCF ubiquitin ligases, we assayed 
ubiquitination of well-established SCF substrates by purified SCF complexes in vitro. 
Indeed, addition of SMER3 to the ligase reactions inhibited ubiquitination of Met4 by 
SCFMet30 in a dose-dependent manner, whereas SMER1 had no effect (Supplementary Fig. 
3). To assess specificity of SMER3 we also examined in vitro ubiquitination of Sic1 by the 
related WD-40 repeat containing SCFCdc4. For direct comparison of SMER3 effects, 
activities of SCFMet30 and SCFCdc4 were analyzed in a single reaction mix containing both 
ligase complexes and their substrates Met4 and Sic1 (Fig. 2d). Due to the faster kinetics of 
the SCFCdc4 catalyzed ubiquitination, the Sic1 reaction was probed at two incubation times: 
first at 5 min corresponding to the linear range for the SCFCdc4 reaction (at which time there 
was no Met4 ubiquitination by SCFMet30), then at 25 min corresponding to the linear range 
of the SCFMet30 reaction. Consistent with the selective in vivo effect of SMER3 on 
SCFMet30, in vitro ubiquitination of Sic1 was unaffected by SMER3 (Fig. 2d and e). In some 
experiments with SCFCdc4, a modest effect is seen on high MW conjugates (data not 
shown), but it is clear from the direct head-to-head comparison where both enzymes are in 
the same tube that there is a very large difference in sensitivity of the two ligase complexes 
towards SMER3.
To investigate the mechanisms of specificity in the inhibition of SCFMet30 by SMER3, we 
examined the association of Met30 and the SCF core component Skp1. We found that 
Met30 was no longer bound to Skp1 in cells treated with SMER3 (Fig. 3a), suggesting that 
SMER3 prevents the assembly of SCFMet30 or induces SCF complex dissociation 
(Supplementary Information). We next asked whether SMER3 affects the binding of other 
Skp1 interactors or acts specifically on SCFMet30. Skp1-bound proteins were purified from 
cells treated with SMER3 or DMSO solvent control and their relative abundance was 
determined using SILAC-based quantitative mass spectrometry. Among the eleven 
identified F-box proteins, only binding of Met30 to Skp1 was significantly inhibited by 
SMER3 (Fig. 3b). Skp1 and Met30 protein levels were not affected by SMER3, nor were the 
interactions of the SCF core components Cdc53 (cullin) and Hrt1 (RING component) with 
Skp1 (Supplementary Fig. 4 and Fig. 3b).
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To further address the specificity of SMER3 for Met30 in vivo, we compared the cell cycle 
arrest phenotype induced by SMER3 to that of temperature-sensitive mutants of Met30, 
Cdc4, and the SCF components induced by non-permissive temperatures. As shown in 
Figure 3c, SMER3 induces a phenotype resembling that of genetic inhibition of Met30, 
while genetic inhibition of general SCF components or the specific F-box subunit Cdc4 
gives a completely different elongated cell cycle arrest phenotype. Inhibition of any of the 
SCF core components simultaneously blocks SCFMet30 and SCFCdc4, yet the arrest 
phenotypes of SCF core mutants strongly resemble Cdc4 inhibition (Fig. 3c). This indicates 
that the cdc4 cell cycle arrest morphology is “dominant” to that of met30 and that inhibition 
by SMER3 is indeed specific for Met30 without affecting Cdc4 or SCF in general. 
Additionally, while SMER3-treated cdc4 temperature-sensitive mutant cells have a 
phenotype at permissive temperatures resembling genetic inhibition of Met30, their 
phenotype changes to that resembling Cdc4 inhibition when shifted to non-permissive 
temperatures (Fig. 3c), further demonstrating that SMER3 has little effect on Cdc4 in vivo.
To test direct binding of SMER3, we employed differential scanning fluorimetry (DSF)16 
using purified Met30-Skp1 vs. Skp1 proteins (Met30 cannot be obtained in isolation without 
Skp1). As shown in Figure 3d, the addition of SMER3 altered the melting temperature of 
Met30-Skp1, but not that of Skp1 alone, indicating that SMER3 does indeed directly target 
the Met30-Skp1 complex. The simplest model to explain the biochemical specificities of 
SMER3 is that it binds directly to Met30 but not Skp1. Since drug binding often stabilizes a 
folded state, or conformation, of its protein target, leading to increased resistance to protease 
digestion (as assayed by DARTS, which stands for drug affinity responsive target 
stability11), we tested whether protease susceptibility of Met30 is altered by the presence of 
SMER3. Indeed, when yeast cell lysates were proteolysed with thermolysin or subtilisin, we 
observed SMER3-dependent protection of Met30 (Fig. 3e, f and Supplementary Fig. 5), but 
not Skp1. These experiments suggest that Met30 is the direct molecular target of SMER3, 
although we cannot exclude that SMER3 binding to Met30 may require Skp1.
Met30 contains at its N-terminus the F-box motif, which binds Skp1, and at the C-terminus 
the WD-40 repeats which serve as protein-protein interaction motifs for substrate binding17. 
We found that the Met30 F-box, but not the Cdc4 F-box, was protected to a similar extent as 
full-length Met30 by the presence of SMER3 in DARTS experiments (Supplementary Figs. 
6 and 7). In contrast, SMER3 failed to protect the WD-40 repeat domain of Met30 
(Supplementary Fig. 6 and Supplementary Information). These results suggest that SMER3 
may recognize the F-box motif of Met30, yet further investigation is required to understand 
how SMER3 binds to Met30.
In this study, we demonstrated that SMER3 (i) specifically inhibits in vitro ubiquitination by 
recombinant reconstituted SCFMet30 (Fig. 2d, e and Supplementary Fig. 3), (ii) selectively 
disassembles or prevents assembly of SCFMet30 but not other SCF complexes in vivo (Fig. 
3a, b, c), and (iii) directly binds to Met30 (or Met30-Skp1 complex), but not Skp1 alone 
(Fig. 3d and e). Together, these experiments suggest that SMER3 specifically inactivates 
SCFMet30 by binding to Met30.
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Historically designing specific inhibitors for SCFs has been considered highly challenging 
due to their common scaffolding subunits and similar enzymatic steps18-21, reminiscent of 
the obstacles faced with kinase inhibitors22. The unexpected biological specificities 
demonstrated by this first-generation hit provide encouraging examples for such potential 
and highlight the importance of unbiased cell-based approaches in drug discovery and in 
biological studies.
In conclusion, we identified several small molecule enhancers of rapamycin from a 
phenotype-based chemical genetic screen. Genomic, genetic, and biochemical analyses 
indicate that one of the SMERs (SMER3) inhibits an E3 ubiquitin ligase in yeast, SCFMet30, 
which coordinates nutritional responses with cell proliferation. Since increasing evidence 
suggests that ubiquitin E3 ligases are involved in tumorigenesis23, we believe that SMER3 
and SMER3-like molecules represent a novel class of E3 ubiquitin ligase inhibitors that can 
potentially be used as anti-cancer drugs in the future.
In addition, our study provides the first link between the TOR pathway and a separate 
network that monitors the sulfur-containing amino acids methionine, cysteine and the 
primary methyl group donor SAM. This genetic interaction may be simply explained by the 
convergence of these two pathways on regulation of the G1 cyclins (refs 14, 24, and see 
Supplementary Table 2 for SMER3). Alternatively, it is possible that more complicated co-
regulations occur in which TOR inhibition, while insufficient for activation of the “sulfur 
starvation” response, may in fact enhance this response during times of sulfur depletion 
(Supplementary Information). Although the target pathway for SMER3 in mammalian cells 
has yet to be elucidated, it is noteworthy that cancer cells and tumors are particularly 
dependent on metabolic networks linked to methionine25, 26, indicating that mammalian 
processes similar to that controlled by SCFMet30 in yeast might provide potential anti-cancer 
targets. Alternatively, or additionally, it is possible that SMER3 may target β-TrCP (ref 27) 
or related SCF(s) in humans whose genome contains many more F-box proteins. Synthetic 
lethal interactions between rapamycin and the ubiquitin-like modification systems (Fig. 2c) 
suggest potential therapeutic benefit for combination therapy with rapamycin and any small 
molecule that inhibits a component of SCF or an activator of SCF, such as in sensitizing a 
tumor's response to rapamycin and/or preempting the development of drug resistance. 
Beyond cancer and tumor-prone syndromes, a variety of other diseases including 
hypertrophy, neurodegeneration and aging are linked to the TOR pathway28, 29. For 
example, several SMERs have been identified which effectively enhance autophagy and 
reduce toxicity in Huntington's disease models through novel, so far unknown, 
mechanisms10. Similar chemical genetic approaches are applicable to the study of other 
pathways, drugs, and diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We are grateful for grant support from ACS and NIH, and for traineeship support of MA and BL by the NIH UCLA 
Chemistry–Biology Interface Predoctoral Training Program. NZ and RJD are investigators of the HHMI. We thank 
Aghajanyy et al. Page 6
Nat Biotechnol. Author manuscript; available in PMC 2011 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
D. Skowyra (Saint Louis University) and M. Tyers (University of Edinburgh, UK) for their generous gifts of 
bacculo virus constructs and anti-Met4 antibody, respectively. We also thank J. Salcedo (Roche Diagnostics 
Corporation) for support towards differential scanning fluorimetry experiments.
References
1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 
124:471–484. [PubMed: 16469695] 
2. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 
4:335–348. [PubMed: 15122205] 
3. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nature 
reviews. 2005; 6:9–20.
4. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006; 25:6436–6446. [PubMed: 
17041628] 
5. Cloughesy TF, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent 
PTEN-deficient glioblastoma. PLoS Med. 2008; 5:e8. [PubMed: 18215105] 
6. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends in molecular 
medicine. 2007; 13:433–442. [PubMed: 17905659] 
7. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 
441:424–430. [PubMed: 16724053] 
8. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell. 2007; 12:9–22. 
[PubMed: 17613433] 
9. Huang J, et al. Finding new components of the target of rapamycin (TOR) signaling network 
through chemical genetics and proteome chips. Proc Natl Acad Sci U S A. 2004; 101:16594–16599. 
[PubMed: 15539461] 
10. Sarkar S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease 
models. Nat Chem Biol. 2007; 3:331–338. [PubMed: 17486044] 
11. Lomenick B, et al. Target identification using drug affinity responsive target stability (DARTS). 
Proc Natl Acad Sci U S A. 2009 in press. 
12. Hughes TR, et al. Functional discovery via a compendium of expression profiles. Cell. 2000; 
102:109–126. [PubMed: 10929718] 
13. Kaiser P, Su NY, Yen JL, Ouni I, Flick K. The yeast ubiquitin ligase SCFMet30: connecting 
environmental and intracellular conditions to cell division. Cell Div. 2006; 1:16. [PubMed: 
16895602] 
14. Patton EE, et al. SCF(Met30)-mediated control of the transcriptional activator Met4 is required for 
the G(1)-S transition. Embo J. 2000; 19:1613–1624. [PubMed: 10747029] 
15. Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of 
dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor 
receptor. J Clin Oncol. 2002; 20:3568–3569. [PubMed: 12202652] 
16. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand 
interactions that promote protein stability. Nat Protoc. 2007; 2:2212–2221. [PubMed: 17853878] 
17. Bai C, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a 
novel motif, the F-box. Cell. 1996; 86:263–274. [PubMed: 8706131] 
18. Zheng N, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. 
Nature. 2002; 416:703–709. [PubMed: 11961546] 
19. Chen Q, et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle 
arrest and activation of autophagy. Blood. 2008; 111:4690–4699. [PubMed: 18305219] 
20. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of 
NF-kappaB signaling. Biochem Biophys Res Commun. 2008; 368:1007–1013. [PubMed: 
18275844] 
21. Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. 
Nature. 2009; 458:732–736. [PubMed: 19360080] 
22. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol. 2005; 12:621–637. 
[PubMed: 15975507] 
Aghajanyy et al. Page 7
Nat Biotechnol. Author manuscript; available in PMC 2011 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
23. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug 
Discov. 2006; 5:596–613. [PubMed: 16816840] 
24. Zinzalla V, Graziola M, Mastriani A, Vanoni M, Alberghina L. Rapamycin-mediated G1 arrest 
involves regulation of the Cdk inhibitor Sic1 in Saccharomyces cerevisiae. Mol Microbiol. 2007; 
63:1482–1494. [PubMed: 17302822] 
25. Halpern BC, Clark BR, Hardy DN, Halpern RM, Smith RA. The effect of replacement of 
methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. 
Proc Natl Acad Sci U S A. 1974; 71:1133–1136. [PubMed: 4524624] 
26. Guo H, et al. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. 
Cancer Res. 1993; 53:5676–5679. [PubMed: 8242623] 
27. Dorrello NV, et al. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein 
translation and cell growth. Science. 2006; 314:467–471. [PubMed: 17053147] 
28. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev 
Pharmacol Toxicol. 2007; 47:443–467. [PubMed: 16968213] 
29. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. 
Nature. 2009; 460:392–395. [PubMed: 19587680] 
30. Flick K, et al. Proteolysis-independent regulation of the transcription factor Met4 by a single Lys 
48-linked ubiquitin chain. Nat Cell Biol. 2004; 6:634–641. [PubMed: 15208638] 
Aghajanyy et al. Page 8
Nat Biotechnol. Author manuscript; available in PMC 2011 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Two unsupervised data analyses classify five SMERs into three different groups based 
on their gene expression profiles
a, Chemical structures of SMER1 to SMER5. b, Two dimensional (2-D) hierarchical 
clustering reveals that the expression profile of SMER1 is similar to that of rapamycin, 
whereas the profiles of SMERs 2, 4 and 5 are indistinguishable from that of DMSO 
(solvent) control. The profile of SMER3 is distinct. Each row corresponds to a gene, and 
each column corresponds to an experimental sample. c, Principal component analysis is 
consistent with hierarchical clustering. Light blue: DMSO; blue: SMER1; cyan: SMER2; 
red: SMER3; sage: SMER4; chartreuse: SMER5; green: rapamycin. Replicates were 
obtained from independent small molecule treatments in separate experiments.
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Figure 2. SMER3 targets SCFMet30
a, Biochemical evidence for SCFMet30 inhibition by SMER3 but not rapamycin. Yeast cells 
were cultured in YPDA medium to mid-log 0.8×107 cells/ml, treated with indicated 
concentrations of SMER3 or rapamycin for 45 min, and total protein was extracted for 
Western blot analyses (Supplementary Information). Met4 ubiquitination in vivo can be 
directly assessed by immunoblotting because ubiquitinated forms of Met4 are not subjected 
to proteasomal degradation and can thus be detected due to a characteristic mobility shift on 
denaturing gels30. Asterisk (*) denotes a non-specific band immuno-reactive to the anti-
Met4 antibody (generous gift from Mike Tyers). b, SMER3 resistance in met4Δ cells. Yeast 
cells were treated with either vehicle (DMSO) or 4 μM SMER3 and growth curve analysis 
was performed with an automated absorbance reader measuring O.D. at 595 nm every 30 
min (Supplementary Information). Cell growth was measured in liquid because SMER3 
activity is undetectable on agar. c, Genetic interaction between SCFMet30 and TOR. 
Temperature sensitive mutants as indicated were grown at 25°C to mid-log phase in YPDA 
medium and serial dilutions were spotted onto plates with or without 2.5 nM rapamycin. The 
plates were incubated at the permissive temperatures for the mutants: 28°C for cdc34-3, 
cdc53-1, cdc4-3 and met30-6 because these mutants exhibited fitness defects at 30°C even 
without rapamycin, or 30°C (standard growth temperature) for met30-9 and skp1-25 because 
these alleles are not temperature sensitive until at 37°C. d, SMER3 specifically inhibits 
SCFMet30 E3 ligase in vitro. Components of SCFMet30 were co-expressed in insect cells and 
the complex was purified based on a GST-tag fused to Skp1. Met4 expressed in insect cells 
was bound to SCFMet30 and the ligase-substrate complex eluted with glutathione. Purified 
ligase-substrate complexes were combined with purified SCFCdc4 and phosphorylated Sic1 
and pre-incubated with DMSO or the indicated concentrations of SMER3 for 20 min at 
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room temperature. The ubiquitination reaction was initiated by addition of E1, E2, ubiquitin, 
and ATP. The reaction was allowed to proceed for 25 min, with an aliquot of the reaction 
collected after the first 5 min to accommodate different reaction kinetics by the two SCFs. 
Reaction products were analyzed by immunoblotting. The asterisks indicate a protein cross-
reacting with the anti-Met4 antibody. e, The amount of un-ubiquitinated substrate (Met4 and 
Sic1) was quantified on a Fuji LAS-4000 imaging system and inhibition was expressed as 
the ratio of un-ubiquitinated substrate in DMSO/SMER3.
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Figure 3. Molecular mechanism for the specificity of SCFMet30 inhibition by SMER3
a, Protein-protein interaction between Met30 and Skp1 is diminished by SMER3 in vivo. 
Yeast strains expressing endogenous 13Myc-tagged Met30 were either untreated, or treated 
with solvent control (DMSO) or 30μM SMER3 for 30 minutes at 30°C. 13MycMet30 was 
immunopurified and immuncomplexes were analyzed for Skp1 binding by Western blot 
analysis. b, SMER3 specifically targets SCFMet30 in vivo as determined by quantitative mass 
spectrometry. A yeast strain expressing endogenous HBTH-tagged Skp1 was grown in 
medium containing either heavy (13C/15N) or light (12C/14N) arginine and lysine to 
metabolically label proteins. The “heavy” culture was treated with solvent control (DMSO) 
and the “light” culture with 20μM SMER3 for 30 minutes at 30°C. Cells were incubated 
with 1% formaldehyde to cross-link and stabilize protein complexes in vivo for 10 minutes 
at 30°C. Cell lysates were prepared under denaturing conditions in 8M urea, mixed at equal 
amounts, and HBTHSkp1-bound complexes were sequentially purified on Ni2+ and 
streptavidin sepharose under fully denaturing conditions. Tryptic peptides of the purified 
complexes were analyzed by LC-MS/MS. Relative abundance of proteins was determined 
by measuring the peptide peak intensities. Abundance ratios for SCF components identified 
by multiple quantifiable peptides are shown as SILAC ratios of “light” (SMER3-treated) 
over “heavy” (DMSO-treated) peptide intensities. c, SMER3 specificity for SCFMet30 vs. 
SCFCdc4 as verified by cell cycle arrest morphology. Temperature sensitive mutants were 
shifted to 37°C for 4 hours. The Skp1 depletion phenotype was observed after repression of 
Skp1 expression in dextrose medium for 12 hours. SMER3 treatment of cells was for 6 
hours. d, SMER3 directly binds to Met30-Skp1, but not Skp1 alone as determined by 
differential scanning fluorimetry (DSF). Met30 and Skp1 were either co-expressed or Skp1 
was expressed alone in insect cells and the complex was purified based on a GST-tag fused 
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to Met30, while Skp1 was purified based on a His-tag fused to Skp1. Protein, drug and 
Sypro Orange dye were added to 384-well plates and melting curve fluorescent signal was 
detected using the LightCycler 480 System II (Roche). Melting temperatures (Tm) were 
determined by the LightCycler 480 Protein Melt Analysis Tool. e, SMER3 protects 
endogenous Met30 from protease digestion. Yeast cells expressing Met30-RGS6H were 
lysed and digested with thermolysin in the presence of SMER3 vs. DMSO control, and 
extent of proteolysis was analyzed by immunoblotting. f, SMER3 protects recombinant 
Met30 from protease digestion. Met30 was PCR-subcloned into pcDNA3.1(-) (Invitrogen) 
and expressed using Promega TnT T7 Quick Coupled Transcription/Translation System. 
Thermolysin digestion was performed using translated lysate incubated with SMER3 or 
vehicle control, and stopped by adding EDTA pH 8.0. Samples were subjected to 4-12% 
NuPAGE gradient gel (Invitrogen) and Western blotted with anti-RGSH (Qiagen) and anti-
GAPDH (Ambion) antibodies. The asterisks (*) indicate the Met30 fragment that is 
protected by SMER3 from protease digestion.
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